论文部分内容阅读
目的探讨替莫唑胺联合放疗对胶质瘤患者血管内皮生长因子(VEGF)、白细胞介素-8(IL-8)表达水平的影响。方法收集广州军区广州总医院及附属157医院2013年9月~2015年12月诊治的胶质瘤患者82例,参照抽签法分成对照组和试验组,各41例,对照组行常规放疗,试验组基于对照组联合替莫唑胺治疗,观察2组治疗后VEGF、IL-8水平、生存质量、临床疗效、不良反应。结果治疗后试验组VEGF(48.69±7.41)、IL-8(30.42±5.31)μg/L低于对照组(97.54±13.68)、(36.08±6.27)μg/L(P<0.05);试验组卡氏功能状态评分(KPS)(85.94±11.52)分高于对照组(73.21±10.68)分(P<0.05);试验组有效率34.15%(14/41)高于对照组16.43%(6/41)(P<0.05);2组总不良反应比较无明显差异(P>0.05)。结论替莫唑胺联合放疗对胶质瘤的治疗能够控制肿瘤进展,降低VEGF、IL-8表达水平。
Objective To investigate the effect of temozolomide combined with radiotherapy on the expression of vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) in patients with glioma. Methods Eighty-two patients with glioma who were diagnosed and treated in Guangzhou General Hospital of Guangzhou and 157 affiliated hospitals of Guangzhou Military Area Command from September 2013 to December 2015 were divided into control group and experimental group according to the drawing method, 41 cases in each group. The control group received routine radiotherapy and experiment Group based on the control group combined with temozolomide treatment, the two groups after treatment VEGF, IL-8 levels, quality of life, clinical efficacy, adverse reactions. Results After treatment, the levels of VEGF (48.69 ± 7.41) and IL-8 (30.42 ± 5.31) μg / L in the experimental group were significantly lower than those in the control group (97.54 ± 13.68) and (36.08 ± 6.27) μg / (KPS) score of 85.94 ± 11.52 was higher than that of the control group (73.21 ± 10.68) (P <0.05). The effective rate of the experimental group was 34.15% (14/41), higher than that of the control group (16.43%, 6/41 ) (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion Temozolomide combined with radiotherapy for glioma can control tumor progression and decrease the expression of VEGF and IL-8.